Humacyte, a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, entered into a credit facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital...
Read Story
December 17, 2025, 08:00 AM
|
CalciMedica, a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, entered into a credit facility...
Read Story
March 06, 2025, 08:03 AM
|
CytoSorbents Corporation, a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that on June 28, 2024, the Company...
Read Story
July 03, 2024, 07:33 AM
|